In a cohort of individuals with type 2 diabetes using the drug sulfasalazine, HbA1c lowering is associated with haematological changes.

Samira M S N'DowLouise A DonnellyEwan R Pearson Graham Rena

Published in: Diabetic medicine : a journal of the British Diabetic Association (2020)

In this observational, population-based study, sulfasalazine initiation was associated with a 6-month reduction in HbA1c . This correlated with haematological changes suggesting haemolytic effects of sulfasalazine. Haemolysis is proposed to contribute to HbA1c lowering through the sulphonamide pharmacophore. This suggests that HbA1c is not a reliable measure of glycaemia in individuals prescribed sulfasalazine.

Keyphrases

molecular docking
emergency department
adverse drug
drug induced
electronic health record